ESMO 2019: KEYNOTE-119 Suggests Activity for Pembrolizumab in Some Triple-Negative Breast Cancer
The phase III KEYNOTE-119 study revealed no significant difference in outcomes with the use of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer. Nevertheless, a pre-planned exploratory analysis suggested that those patients with the highest tumor and immune cell expression of PD-L1 may benefit from this drug. The findings were presented here at the European Society for Medical Oncology (ESMO) Congress 2019, taking place from September 27 to October 1.